Evidence map›Paper›PMID 37739311›Full record

ArticleThe journal of allergy and clinical immunology. In practice2024

Vancomycin-Induced Liver Injury, DRESS, and HLA-A∗32:01.

Bilal A Asif, Christopher Koh, Elizabeth J Phillips, Jiezhun Gu, Yi-Ju Li, Huiman Barnhart, Naga Chalasani, Robert J Fontana, Paul H Hayashi, Victor J Navarro and 2 more

Open access · greenAbstract read
In one paragraph

Article in The journal of allergy and clinical immunology. In practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 2 countries.

Bilal A AsifLiver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Bethesda, Md. Electronic address: bilal.a.asif@gmail.com.
Christopher KohLiver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Bethesda, Md. Electronic address: christopher.koh@nih.gov.
Elizabeth J PhillipsDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tenn.
Jiezhun GuDuke Clinical Research Institute, Duke University, Durham, NC.
Yi-Ju LiDuke Clinical Research Institute, Duke University, Durham, NC.
Huiman BarnhartDuke Clinical Research Institute, Duke University, Durham, NC.
Naga ChalasaniDepartment of Medicine, Indiana School of Medicine, Indianapolis, Ind.
Robert J FontanaDepartment of Medicine, University of Michigan School of Medicine, Ann Arbor, Mich.
Paul H HayashiDivision of Hepatology and Nutrition, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Md.
Victor J NavarroDepartment of Medicine, Einstein Healthcare Network, Philadelphia, Pa.
Jay H HoofnagleLiver Disease Research Branch, Division of Digestive Diseases and Nutrition, NIDDK, NIH, Bethesda, Md.
Drug Induced Liver Injury Network (DILIN)
Duke University · USNational Institutes of Health · USCenter for Drug Evaluation and Research · USEinstein Healthcare Network · USIndiana University – Purdue University Indianapolis · USNational Institute of Diabetes and Digestive and Kidney Diseases · USUniversity of Michigan · USVanderbilt University Medical Center · US

Funding

Immune Tolerance Network UM1 2023 SupplementUM1AI109565 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI Mark S Anderson, Jane Hoyt Buckner · 2014 to 2026
$451.6M
NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisU01AI154659 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2020 to 2025
$15.5M
Michigan Hepatotoxicity Clinical Research Network Renewal 2018U01DK065184 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ROBERT J FONTANA · 2003 to 2026
$7.0M
Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivorsR01HG010863 · NHGRI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2019 to 2022
$3.1M
Management and Treatment of Chronic Delta Hepatitis Infection and other Liver DiseasesZIADK075150 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI KOH, CHRISTOPHER · 2019 to 2025
$2.8M
Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study)R01AI152183 · NIAID · UNIVERSITY OF CAPE TOWN · PI MEINTJES, GRAEME AYTON, PHILLIPS, ELIZABETH · 2020 to 2025
$1.6M
Stevens-Johnson syndrome/toxic epidermal necrolysis 2021: Collaboration, Innovation and CommunityR13AR078623 · NIAMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2021 to 2021
$33k
Intramural NIH HHS Z99 DK999999Intramural NIH HHS ZIA DK075150NHGRI NIH HHS R01 HG010863NIAID NIH HHS R01 AI152183NIAID NIH HHS U01 AI154659NIAID NIH HHS UM1 AI109565NIAMS NIH HHS R13 AR078623NIDDK NIH HHS U01 DK065184
6 · The paper itself

Abstract

backgroundIntravenous vancomycin therapy can cause liver injury as well as "drug reaction with eosinophilia and systemic symptoms" (DRESS) syndrome. This study aimed to better define the clinical features and HLA associations of vancomycin-induced liver injury.

objectiveTo describe clinical, biochemical, and temporal characteristics of vancomycin-induced liver injury.

methodsCases of liver injury with recent exposure to vancomycin who were enrolled in the US Drug-induced Liver Injury Network between 2004 and 2020 were assessed. Sequencing of HLA alleles was performed on stored blood samples.

resultsAmong 1697 cases of drug-induced liver injury identified between 2004 and 2021, 9 (0.5%) were attributed to intravenous vancomycin. The 9 cases included 6 men, median age 60 years (range, 23-85 days), and treatment for 26 days (range, 1-34 days). The clinical presentation was DRESS syndrome in 8 patients, of whom 6 received corticosteroids. Liver injury varied from hepatocellular to cholestatic and from mild (n = 5) to fatal (n = 1). In survivors, liver injury and DRESS syndrome ultimately resolved. HLA typing demonstrated the HLA-A∗32:01 allele in 7 vancomycin cases (78%, all with DRESS syndrome), versus 1 of 81 cases (1.2%) exposed but not attributed to vancomycin, and 113 of 1708 cases (6.6%) without vancomycin exposure. The allele frequency in vancomycin cases was 0.44 compared with less than 0.04 in US populations.

conclusionsVancomycin-induced liver injury is commonly associated with DRESS syndrome and linked to HLA-A∗32:01. HLA-A∗32:01 testing could be considered early to risk-stratify patients using long-term intravenous vancomycin therapy.

Indexed as

Chemical and Drug Induced Liver InjuryChemical and Drug Induced Liver Injury, ChronicDrug Hypersensitivity SyndromeEosinophiliaFemaleHLA-A AntigensHumansMaleMiddle AgedVancomycinHLA-A AntigensVancomycinDRESS syndromeDrug-induced liver injuryHLA-A∗32:01HLA testingVancomycin

Identifiers

PMID37739311
PMCPMC10885131
OpenAlexW4386898678

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.